Investors & Media

Corporate Overview

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune Stimulating Antibody Conjugate (ISAC) clinical candidate targeting Claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of 6 different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies.


May 14, 2024

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamRead More

March 21, 2024

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateRead More

February 27, 2024

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceRead More

View All News Releases


May 14, 2024 at 4:30 PM EDT

Bolt Biotherapeutics Q1 2024 Strategic Update Call Read More

March 5, 2024 at 2:50 PM EST

TD Cowen 44th Annual Healthcare Conference Read More

December 6, 2023 at 1:00 PM EST

2023 San Antonio Breast Cancer Symposium Read More

View All Upcoming Events